重组人脑利钠肽对心肾综合征患者心、肾功能的影响研究

摘要

Objective To investigate the impact of recombinant human brain natriuretic peptide on cardiac and renal function in patients with cardio-renal syndrome(CRS).Methods From 2016 to 2017,a total of 80 patients with CRS were selected in the Department of Cardiology,the Fourth People's Hospital of Zigong,and they were divided into control group and study group according to random number table,each of 40 cases. Patients in control group received conventional medical treatment and continuous renal replacement therapy,while patients in study group received extra recombinant human brain natriuretic peptide based on that of control group;both groups continuously treated for 14 days. Clinical effect,index of cardiac and renal function before and after treatment were compared between the two groups.Results No statistically significant differences of clinical effect was found between the two groups(P>0.05). No statistically significant differences of serum NT-proBNP level,SV or LVEF was found between the two groups before treatment(P>0.05);after treatment,serum NT-proBNP level in study group was statistically significantly lower than that in control group,while LVEF and SV in study group were statistically significantly higher than those in control group(P<0.05). No statistically significant differences of BUN, Cr or GFR was found between the two groups before treatment(P>0.05);after treatment,BUN and Cr in study group were statistically significantly lower than those in control group,while GFR in study group was statistically significantly higher than that in control group(P<0.05).Conclusion Recombinant human brain natriuretic peptide can can effectively improve the cardiac and renal function in patients with CRS.%目的 探讨重组人脑利钠肽治疗心肾综合征(CRS)对患者心、肾功能的影响.方法 选取2016—2017年自贡市第四人民医院心内科收治的CRS患者80例,采用随机数字表法分为对照组与研究组,每组40例.对照组患者给予常规药物及连续性肾脏替代治疗(cRRT),研究组患者在对照组基础上加用重组人脑利钠肽;两组患者均连续治疗14 d.比较两组患者临床疗效,治疗前后心、肾功能指标.结果 两组患者临床疗效比较,差异无统计学意义(P>0.05).治疗前两组患者血清N末端B型利钠肽前体(NT-proBNP)水平、每搏输出量(SV)、左心室射血分数(LVEF)比较,差异无统计学意义(P>0.05);治疗后研究组患者血清NT-proBNP水平低于对照组,LVEF、SV高于对照组(P<0.05).治疗前两组患者尿素氮(BUN)、肌酐(Cr)、肾小球滤过率(GFR)比较,差异无统计学意义(P>0.05);治疗后研究组患者BUN、Cr低于对照组,GFR高于对照组(P<0.05).结论 重组人脑利钠肽治疗能有效改善CRS患者心、肾功能.